Daily Sepsis Research Analysis
Analyzed 39 papers and selected 3 impactful papers.
Summary
Top studies today span clinical and mechanistic sepsis research. A large multicenter RCT in pediatric septic shock found no difference between balanced crystalloids and 0.9% saline for MAKE30, though balanced fluids reduced hyperchloremia. A mechanistic Science Advances study identified a conserved NFATc1-dependent enhancer controlling B cell IL-10 and survival in endotoxemic sepsis, while a multicenter cohort linked unfractionated heparin to lower ICU mortality in sepsis-associated liver injury.
Research Themes
- Fluid resuscitation strategy in pediatric septic shock
- B cell NFATc1–CNS enhancer axis governing IL-10 and sepsis survival
- Anticoagulation signals in sepsis-associated liver injury (heparin and DRR stratification)
Selected Articles
1. Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock.
In 8482 analyzed children with suspected septic shock, balanced crystalloids did not reduce MAKE30 versus 0.9% saline (3.4% vs 3.0%; RR 1.10; P=0.85). Balanced fluids reduced hyperchloremia and hypernatremia without affecting hospital-free days or other safety outcomes.
Impact: A rigorously executed, multinational RCT directly informs first-line fluid choice in pediatric septic shock and demonstrates equivalence for kidney-related outcomes while detailing biochemical differences.
Clinical Implications: Either balanced crystalloids or 0.9% saline are reasonable for resuscitation in pediatric septic shock; balanced fluids lower hyperchloremia risk. Fluid selection can be individualized based on electrolyte profiles and availability while focusing on timely antibiotics and vasoactive support.
Key Findings
- No difference in MAKE30 between balanced crystalloids and 0.9% saline (3.4% vs 3.0%; RR 1.10; 95% CI, 0.88–1.40; P=0.85).
- Hospital-free days were identical (median 23 days in both groups).
- Balanced fluids reduced hyperchloremia (31.4% vs 49.0%) and hypernatremia (1.8% vs 3.1%) but had higher hyperlactatemia (19.8% vs 16.7%).
Methodological Strengths
- Pragmatic, multicenter randomized design with large sample size across five countries
- Clinically meaningful composite kidney endpoint and intention-to-treat analysis
Limitations
- Open-label pragmatic design with potential for co-intervention variability
- Enrollment based on suspected septic shock may include diagnostic heterogeneity
Future Directions: Assess subgroup effects (e.g., severe hyperchloremia risk, traumatic brain injury) and long-term kidney outcomes; evaluate fluid strategies integrated with vasopressor timing and electrolyte-guided protocols.
BACKGROUND: Whether treatment with balanced crystalloid fluid leads to better outcomes than 0.9% saline in children treated for septic shock is debated. METHODS: In this pragmatic clinical trial conducted at 47 emergency departments in five countries, patients (2 months to <18 years of age) with suspected septic shock and abnormal perfusion were randomly assigned to receive fluid resuscitation with either balanced fluid or 0.9% saline for up to 48 hours. The primary outcome was a major adverse kidney event (a composite of death, new renal-replacement therapy, or persistent kidney dysfunction) at 30 days after enrollment or hospital discharge, whichever occurred first. RESULTS: Of 9041 enrolled patients, 277 (6.1%) in the balanced-fluid group and 282 (6.2%) in the 0.9%-saline group withdrew from the trial, leaving 4235 and 4247 patients, respectively, for analysis. A primary-outcome event occurred in 137 patients (3.4%) in the balanced-fluid group and in 124 (3.0%) in the 0.9%-saline group (difference, 0.4 percentage points; 95% confidence interval [CI], -0.5 to 1.3; risk ratio, 1.10; 95% CI, 0.88 to 1.40; P = 0.85). The median number of hospital-free days during 28 days after enrollment was 23 (interquartile range, 19 to 25) in both groups. Hyperchloremia occurred in 868 patients (31.4%) in the balanced-fluid group and in 1383 (49.0%) in the 0.9%-saline group; hypernatremia in 52 (1.8%) and 89 (3.1%), respectively; and hyperlactatemia in 260 (19.8%) and 228 (16.7%). No differences in other safety outcomes or adverse events were seen. CONCLUSIONS: Among children treated for septic shock, no significant difference was seen in the incidence of death, new renal-replacement therapy, or persistent kidney dysfunction when fluid resuscitation was administered with balanced fluid as compared with 0.9% saline. (Funded by Eunice Kennedy Shriver National Institute of Child Health and Human Development and others; PRoMPT BOLUS ClinicalTrials.gov number, NCT04102371.).
2. Conserved noncoding sequence-9 regulates NFATc1-mediated IL-10 expression in B cells to control inflammatory responses.
This mechanistic study identifies a conserved enhancer (CNS-9/CNS-12) bound by NFATc1 that drives B cell IL-10 expression, with loss impairing survival in LPS-induced sepsis. B1a cells are the predominant IL-10-producing B cells under this regulation, highlighting a potential immunoregulatory therapeutic axis.
Impact: Reveals a previously undefined, conserved regulatory element controlling B cell IL-10 with direct impact on sepsis survival in vivo, advancing immunometabolic understanding and therapeutic targeting.
Clinical Implications: While preclinical, the NFATc1–CNS enhancer axis offers a rationale to augment B cell IL-10 in hyperinflammatory sepsis and may guide biomarker development for regulatory B cell activity.
Key Findings
- CNS-9 acts as an NFATc1-bound enhancer promoting chromatin looping to the IL-10 promoter in B cells.
- B1a cells are the main B cell source of IL-10 under NFATc1–CNS-9 regulation.
- Deletion of CNS-9 or B cell–specific NFATc1 reduces IL-10, heightens inflammation, and decreases survival in LPS-induced sepsis.
- The human homolog CNS-12 exhibits similar NFATc1-dependent enhancer function.
Methodological Strengths
- Integrative approach including genomic enhancer mapping, chromatin conformation, cell phenotyping, and in vivo survival
- Cross-species validation demonstrating a human homolog (CNS-12) with conserved function
Limitations
- LPS-induced endotoxemia may not capture the full complexity of human sepsis pathophysiology
- Therapeutic modulation of the enhancer axis was not directly tested with pharmacologic tools
Future Directions: Develop pharmacologic or gene-targeting strategies to modulate the NFATc1–CNS enhancer axis; evaluate effects in polymicrobial sepsis and human tissues; explore biomarker potential of B cell IL-10 programs.
Interleukin-10 (IL-10) production by B cells plays a critical role in regulating inflammatory responses, yet the mechanisms controlling its expression remain poorly understood. We identified a conserved noncoding sequence (CNS-9) as an essential regulatory element for IL-10 expression in mouse B cells. Comprehensive genomic analyses revealed that CNS-9 functions as an enhancer bound by the transcription factor NFATc1, which facilitates chromatin looping between CNS-9 and the IL-10 promoter to drive transcription. Flow cytometry analyses identified B1a cells as the predominant source of B cell-derived IL-10, with this production critically dependent on NFATc1-mediated CNS-9 regulation. In a mouse model of LPS-induced sepsis, deletion of CNS-9, B cell-specific NFATc1, or both resulted in reduced IL-10 production, exacerbated inflammatory responses, and decreased survival. Furthermore, we demonstrated that the human homolog, CNS-12, functions similarly through NFATc1-dependent mechanisms. These findings establish a conserved regulatory pathway controlling IL-10 expression in B cells with notable implications for inflammatory disease pathogenesis and potential therapeutic interventions.
3. De Ritis Ratio and Heparin Therapy in Sepsis-Associated Liver Injury: A Multicenter Cohort Study.
Across MIMIC-IV and eICU cohorts, unfractionated heparin therapy was associated with substantially lower ICU mortality in sepsis-associated liver injury after propensity matching and multistate modeling. The De Ritis ratio identified high-risk patients but did not predict differential heparin benefit.
Impact: Provides externally validated, real-world evidence suggesting mortality benefit of UFH in SALI and clarifies that DRR is prognostic but not predictive, shaping the design of future trials.
Clinical Implications: Routine UFH use for SALI cannot be recommended without RCTs, but clinicians may consider enrollment in anticoagulation trials; DRR can assist in risk stratification, not treatment selection.
Key Findings
- UFH therapy was associated with lower ICU mortality after propensity score matching in MIMIC-IV (HR 0.34, 95% CI 0.28–0.42).
- Findings were reproduced in eICU (HR 0.43, 95% CI 0.29–0.65) and consistent in MSCM analyses (HR 0.22, 95% CI 0.17–0.30).
- The De Ritis ratio identified high-risk patients, but there was no significant interaction indicating differential UFH benefit by DRR.
Methodological Strengths
- Large, multicenter EHR cohorts with external validation
- Use of propensity score matching and multistate competing risks modeling to mitigate confounding
Limitations
- Retrospective observational design with potential residual confounding and indication bias
- Heterogeneity in UFH dosing/timing and limited safety (bleeding) data in the abstract
Future Directions: Prospective randomized trials of UFH in SALI with standardized dosing, bleeding surveillance, and biomarker-driven stratification, including DRR and thromboinflammatory markers.
BACKGROUND: Sepsis-associated liver injury (SALI) is a highly heterogeneous thromboinflammatory disorder with no specific treatment. The De Ritis ratio (DRR, aspartate aminotransferase/alanine aminotransferase) stratifies mortality risk, and unfractionated heparin (UFH) possesses pleiotropic effects that may attenuate thromboinflammation. We investigated whether DRR identifies a SALI subphenotype that derives differential benefit from UFH therapy. METHODS: This retrospective multicenter cohort study included 9,561 SALI patients from the Medical Information Mart for Intensive Care IV (MIMIC-IV; RESULTS: UFH therapy was associated with significantly reduced ICU mortality after PSM in both cohorts MIMIC-IV (hazard ratio [HR]: 0.34, 95% confidence interval [CI]: 0.28-0.42) and eICU (HR: 0.43, 95% CI: 0.29-0.65), with consistent results in MSCM analyses (HR: 0.22, 95% CI: 0.17-0.30). Subgroup analysis suggested numerical benefit in patients with DRR > 1, but formal tests for interaction were not significant in either cohort (MIMIC-IV: CONCLUSION: UFH therapy is associated with reduced mortality in SALI patients. Although DRR identifies a high-risk subgroup, the lack of significant interaction precludes its use as a predictive biomarker for UFH response. A prospective randomized trial is warranted to validate these findings and DRR-stratified UFH benefits.